Microsaic jumps following mass spectrometry breakthrough

Microsaic Systems surged on Monday after reporting a technological breakthrough that it says could provide customers with "significant" cost and time savings.

The mass spectrometry instrument developer said that it has developed proof of concept workflows to analyse in real-time complex samples from bioreactors, allowing customers to replace expensive analysers that have been a mainstay of bio-analysis.

Glenn Tracey, chief executive of Microsaic, said: "As our technology can measure small and large molecules simultaneously, we can potentially replace workflows which use several analysis techniques costing hundreds of thousands of pounds each in capital expenditure. Additionally, because our technology is 'label-free', Microsaic can potentially save hours of workflow time and provide a significant saving in reagent costs."

Tracey added that new demands on bioprocessing mean that there is a requirement for real-time information, highlighting the importance of the AIM traded company's technology's ability to sample the media from a bioreactor in real-time to provide critical information regarding process monitoring and quality attributes of the end-product.

Microsaic Systems' shares were up 8.00% at 1.43p at 1044 BST.